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Abstract
Background: The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified
bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori
resistance to tetracycline or to amoxicillin is relatively low. A 14-day modified bismuth quadruple protocol as first-
line H. pylori treatment was compared with 10-day sequential therapy.
Methods: In total, 390 H. pylori-infected subjects participated in the randomized clinical trial: 10-day sequential
therapy (40 mg pantoprazole plus 1 g amoxicillin twice a day for 5 days, then 40 mg pantoprazole and 500 mg
clarithromycin twice a day and 500 mg metronidazole three times a day for 5 days) or 14-day modified bismuth
quadruple therapy (40 mg pantoprazole, 600 mg bismuth subcitrate, 1 g tetracycline, and 1 g amoxicillin, twice a
day). 13C-urea breath test, rapid urease testing, or histology was performed to check for eradication.
Results: Intention-to-treat (ITT) eradication rates of 10-day sequential and 14-day quadruple therapy were 74.6 %
and 68.7 %, respectively, and the per-protocol (PP) rates were 84.2 and 76.5 %, respectively. The eradication rate
was higher in the sequential therapy group, but neither the ITT nor the PP analyses had a significant
difference (P = 0.240 and P = 0.099, respectively). However, the adverse events were significantly lower in the
modified bismuth quadruple therapy group than the sequential therapy group (36.9 vs. 47.7 %, P = 0.040).
Conclusions: Ten-day sequential therapy appears to be more effective despite frequent adverse events.
However, both 10-day SQT and 14-day PBAT did not reach the excellent eradication rates that exceed 90 %.
Additional trials are needed to identify a more satisfactory first-line eradication therapy.
Trial registration: ClinicalTrials.gov (NCT02159976); Registration date: 2014-06-03, CRIS (KCT0001176);
Registration date: 2014-07-23.
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Background
Helicobacter pylori is a major cause of gastric diseases
such as chronic gastritis, gastroduodenal ulcers, and gastric
cancer, and it is well known that the eradication of H. pylori
is important in preventing and treating these gastric diseases
[1, 2]. Recently, the Kyoto Global Consensus Meeting, held
in Japan in early February of 2014, presented radical changes
in the diagnosis and treatment of H. pylori infection, such as
recommending eradication treatment for patients with dys-
pepsia [3]. In addition, eradication therapy was recom-
mended for all H. pylori-positive individuals for the purpose
of preventing H. pylori-related diseases [3]. However, the
eradication rates of first-line triple therapy, which consists of
a proton pump inhibitor (PPI) and two antibiotics (clarithro-
mycin and amoxicillin), have been continuously decreasing
[4]. Only ~18 % of previous studies have reported exceeding
85 % eradication on an intention-to-treat (ITT) analysis,
with ~60 % falling short of 80 % [5]. The reason for the de-
crease in the efficacy of PPI-based triple therapy is mainly
due to the increase in H. pylori resistance to clarithromycin.
As such, in Western countries, standard triple therapy is
currently considered a “legacy therapy” [5]. In fact, recent
European guidelines recommended triple therapy as the
first-line treatment only when the prevalence of clarithromy-
cin resistance is under 20 % [6].
To overcome this unsatisfactory eradication rate, se-
quential therapy (SQT) is currently recommended as an
alternative first-line treatment for H. pylori infection.
Many European randomized clinical trials (RCTs) and
meta-analyses have shown the superiority of SQT over
standard PPI-based triple therapy [7–9]. In a Korean
meta-analysis based on six RCTs, the eradication rate of
SQT was 79.4 % in ITT analysis and 86.4 % in PP ana-
lysis; this meta-analysis also proved that SQT is superior
to standard PPI-based triple therapy (relative risk [RR]
1.761, 95 % confidence interval [CI]; 1.403–2.209) [10].
However, the eradication rate of SQT in Korea, mostly
under 80 % (ITT: 79.4 %, 95 % CI: 76.3–82.2) [10], is not
satisfactory and is about 10 % lower than reported in
early European studies [10, 11]. This suboptimal eradica-
tion rate could be explained by high rates of antibiotic
resistance, especially to clarithromycin, metronidazole,
or both [12]. Previous studies showed that the rate of re-
sistance to clarithromycin was >20 %, that to metronida-
zole was >30 %, and that to both was >10 % [13, 14].
The classical bismuth quadruple therapy, which con-
sists of a PPI, bismuth, tetracycline, and metronidazole,
is frequently used as a first- or second-line regimen [6,
15–17]. However, it is known that more than 30 % of pa-
tients stop taking their medicine due to the complicated
regimen and the high rate of adverse events [18]. In view
of antibiotic resistance, a modified bismuth quadruple
therapy (PBAT), in which metronidazole is replaced with
amoxicillin, is very attractive because many studies have
reported that H. pylori resistance to amoxicillin and
tetracycline is low [19] and furthermore, amoxicillin is
easier to take in comparison to metronidazole. Several
studies have suggested good eradication rates with this
amoxicillin and tetracycline combined quadruple regi-
men [20–23]; however, the reported efficacies are con-
flicting. From this background the aim of this study was
to evaluate the efficacy of 14-day PBAT as a first-line
treatment and compare 10-day SQT to 14-day PBAT in
order to establish a more effective first-line regimen for
H. pylori in terms of eradication rate and adverse effects.
Methods
Study design and participants
A prospective, multi-center, randomized, open-label, paral-
lel design clinical trial was conducted between July 2014
and May 2015 in 14 tertiary hospitals from different regions
in Korea. Inclusion criteria were adult Korean men and
women (aged ≥ 18 years) who were diagnosed as H. pylori-
positive by any of the following three methods: 1) a positive
rapid urease test (CLOtest [Delta West, Bentley, Australia]),
2) histologic evidence of H. pylori by modified Giemsa
staining, or a 3) positive 13C-urea breath test. Exclusion cri-
teria were 1) age under 18 years; 2) previous eradication
therapy for H. pylori; 3) drugs that could influence the
study results such as a PPI, H2 blocker, mucosal protective
agent, or antibiotics within the prior 4 weeks; 3) previous
gastric surgery; 4) advanced gastric cancer or other malig-
nancy; 5) abnormal liver function or liver cirrhosis; 6) ab-
normal renal function or chronic kidney disease; 7) other
severe concurrent diseases; 8) previous contraindications or
allergic reactions to the study drugs; 9) genetic disorders
such as galactose intolerance, the Lapp lactase deficiency,
or glucose-galactose malabsorption; 10) mental disorders or
alcohol or drug addiction; 11) pregnancy or lactation or re-
fusal to use an appropriate method of contraception
throughout the course of the study; 12) any condition that
might affect the evaluation of the clinical results in the
judgment of the principal investigator or sub-investigator;
or 13) any specific contraindication to the study drugs.
The study protocol was approved by the Korean Food
and Drug Administration (KFDA No. 30157) and by the
Institutional Review Board and Ethics Committees of all
participating hospitals (Additional file 1). The study was
performed according to Good Clinical Practices (GCP)
and the Declaration of Helsinki, and written informed
consent was obtained from all patients before enroll-
ment. In addition, this study protocol has been regis-
tered at ClinicalTrials.gov (NCT02159976) and Clinical
Research Information Service (CRIS) (KCT0001176).
Randomization and treatment allocation
An independent statistician at Seoul National University
Bundang Hospital (SNUBH) prepared the randomization.
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The subjects were randomized in a 1:1 ratio by a block
randomization method to receive either 10-day SQT or
14-day PBAT. The 10-day SQT consisted of 40 mg of pan-
toprazole plus 1 g of amoxicillin twice a day for the initial
5 days, followed by 40 mg of pantoprazole and 500 mg of
clarithromycin twice a day and 500 mg of metronidazole
three times a day for the subsequent 5 days. The 14-day
PBAT consisted of 40 mg of pantoprazole, 600 mg of bis-
muth subcitrate, 1 g of tetracycline, and 1 g of amoxicillin,
twice a day. Four weeks after completing the therapy, suc-
cessful H. pylori eradication was defined by a negative 13C-
urea breath test or an invasive test when endoscopic
follow-up was needed in cases of benign gastric ulcer. The
drug compliance and adverse events were evaluated by a
physician via direct questioning. Compliance was consid-
ered to be satisfactory when drug intake exceeded 85 %.
Assessment of H. pylori infection
Invasive H. pylori test (Giemsa histology and CLOtest)
To determine the presence of current H. pylori infection,
four biopsy specimens (one each from the greater curva-
ture and lesser curvature of the antrum and body) were
taken from the gastric mucosa at each endoscopic examin-
ation and were fixed in formalin to be used for the evalu-
ation of H. pylori infection by Giemsa staining [24]. Two
specimens from the lesser curvature of the antrum and
body were used for the rapid urease test (CLOtest) [24].
13C-urea breath test
Subjects were fasted for 4 h prior to testing and a pre-
dose breath sample was obtained; 100 mg of 13C-urea
powder (UBiTkit; Otsuka Pharmaceutical Co. Ltd., Tokyo,
Japan) dissolved in 100 mL of water was then adminis-
tered orally, and a second breath sample was collected
20 min later. The cutoff value was 2.5 %. The collected
samples were analyzed using an isotope ratio mass spec-
trometer (UBiT-IR300; Otsuka Pharmaceutical Co., Ltd.).
Trial outcomes
The primary outcome was comparing the percentage of
participants with successful H. pylori eradication in the
10-day SQT and 14-day PBAT groups 4–6 weeks after
completion of eradication therapy. The secondary out-
come was to compare the percentage of patients whose
drug compliance was greater than 85 % and the percent-
age of adverse events in the 10-day SQT and 14-day
PBAT groups.
Sample size and statistical analysis
Because the eradication rate of the 10-day SQT was
found to be 82.0 % in a previous Korean report [10] the
eradication rate of the 14-day PBAT was assumed to be
similar to that of the 10-day SQT if the rate difference
between the two regimens was less than 10 %. With a
power of 80 % at a two-sided type 1 error rate of 5 %, 195
subjects were needed for each treatment arm to allow for
10 % loss to follow-up. The H. pylori eradication rate was
determined by both an ITT and a per-protocol (PP) ana-
lysis. All subjects who received treatment were included
in the ITT analysis. For the PP analysis, subjects who were
lost to follow-up, had taken less than 85 % of the pre-
scribed drugs, or had dropped out due to severe adverse
events were excluded.
Parametric continuous variables were compared using
the Student’s t-test and are presented as mean ± standard
deviation (SD). Categorical variables were analyzed using
Pearson’s chi square test or Fisher’s exact test and were pre-
sented as numbers (percentages). Univariate and multivari-
ate logistic regression were used for analysis of influencing
factors, which were expressed as the odds ratios (OR) and
95 % confidence intervals (CI). A two-sided P value of less
than 0.05 was considered statistically significant. All statis-
tical analyses were performed using SPSS (version 20.0;
SPSS Inc., Chicago, IL, US).
Results
Subjects
A total of 390H. pylori-infected treatment-naïve subjects
were randomly assigned to the 10-day SQT group (n = 195)
or the 14-day PBAT group (n = 195) (Fig. 1). Nineteen sub-
jects in the SQT group and 18 subjects in the PBAT group
did not complete the study due to adverse events, loss of
follow-up, or withdrawal of consent. Therefore, 176 sub-
jects in the SQT group and 175 subjects in the PBAT group
completed the follow-up. After exclusion of 11 and 7 non-
compliant subjects who consumed <85 % of the prescribed
medications, 165 and 170 subjects in the SQT and PBAT
groups, respectively, became the objects of the PP analysis
(Fig. 1). There were no significant differences in the base-
line characteristics or endoscopic findings between the two
groups (Table 1).
Eradication rates
ITT eradication rates of the 10-day SQTand 14-day PBAT
groups were 74.6 % (146/195) and 68.7 % (134/195) and
the PP eradication rates were 84.2 % (139/165) and 76.5 %
(130/170), respectively. The eradication rate was higher in
the SQT than the PBAT group, but there was no statistical
significance on either ITT or PP analysis (P = 0.240 and
P = 0.099, respectively) (Fig. 2). There also was no stat-
istical significance in the ITT analysis conducted inde-
pendently at each institution (Fig. 3).
Compliance and adverse events
The complete follow-up rate was 90.3 % (176/195) in
the 10-day SQT and 90.8 % in the 14-day PBAT group.
The numbers of subjects who took more than 85 % of
the prescribed medicine were 93.8 % (165/176) in the
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10-day SQT group and 96.1 % (170/177) in the 14-day
PBAT group. There was also no significant difference be-
tween the two groups (P = 0.460). Ninety-three patients
(47.7 %) who took the sequential regimen and 72 pa-
tients (36.9 %) who took the quadruple regimen experi-
enced at least one adverse event. The adverse event rate
was significantly lower in the PBAT group than in the
SQT group (P = 0.040). In the 10-day SQT group, the
most frequent adverse events were taste distortion
(25.8 %) and abdominal bloating (22.6 %). In the 14-day
PBAT group, the most frequent adverse events were epi-
gastric discomfort (23.6 %) and diarrhea (16.7 %). Taste
distortion was more frequently reported in the 10-day
SQT group (P < 0.001) and diarrhea was more frequently
reported in the 14-day PBAT group (P = 0.014) (Table 2).
Factors associated with eradication failure in PBAT
On univariate analysis, male sex (OR, 0.38; 95 % CI,
0.31–1.30) and BMI ≥ 25 kg/m2 (OR, 2.28; 95 % CI,
1.12–4.63) were associated with treatment failure in the
14-day PBAT group. The multivariate analysis confirmed
that both male sex (OR, 0.27; 95 % CI, 0.34–1.51) and
BMI (OR, 2.16; 95 % CI, 1.05–4.43) were associated with
treatment failure in the 14-day PBAT group (Table 3).
Discussion
Antibiotic resistance is one of the main causes of treatment
failure in H. pylori eradication. The rates of clarithromycin
195 Assigned to 
Sequential (SQT)









3 For adverse events
14 Lost to follow-up
2 withdrew consent
18 Discontinued study
3 For adverse events
13 Lost to follow-up
2 withdrew consent
11 non compliant 7 non compliant
Intention to treat
Per Protocol
Fig. 1 Flowchart of participants
Table 1 Baseline characteristics of the subjects
SQT (n = 195) PBAT (n = 195) p-value
Gender, n (%) 0.184
Male 103 (52.8) 117 (60.0)
Female 92 (47.2) 78 (40.0)
Age (mean ± SD), year 53.1 ± 12.6 53.6 ± 13.2 0.697
BMI, kg/m2 23.5 ± 3.1 23.9 ± 3.4 0.328
Smoking, n (%) 38 (19.5) 36 (18.5) 0.897
Alcohol, n (%) 75 (38.5) 72 (36.9) 0.835
Endoscopic finding, n (%)
Normal 10 (5.1) 11 (5.6) 1.000
Atrophic gastritis with or
without intestinal metaplasia
43 (22.1) 31 (15.9) 0.155
Other gastritis 12 (6.2) 16 (8.2) 0.556
Gastric ulcer 47 (24.1) 43 (22.1) 0.718
Duodenal ulcer 15 (7.7) 20 (10.3) 0.479
Gastric ulcer + Duodenal
ulcer
4 (2.1) 7 (3.6) 0.541
EMR, ESD for dysplasia
or EGC
16 (8.2) 18 (9.2) 0.858
MALToma 1 (0.5) 0 (0.0) 1.000
Reflux esophagitis 1 (0.5) 3 (1.5) 0.615
Others 10 (5.1) 7 (3.6) 0.620
SQT sequential therapy, PBAT quadruple therapy consist of pantoprazole,
bismuth, amoxicillin, and tetracycline, BMI body mass index, EMR endoscopic
mucosal resection, ESD endoscopic submucosal dissection, EGC early gastric
cancer, MALToma mucosal associated lymphoid tissue lymphoma
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resistance increased rapidly from 23.2 to 37.3 % from 2003
to 2012 and the metronidazole resistance rate was 35.8 %
between 2009 and 2012 in Korea [4]. In contrast, the rates
of resistance to amoxicillin and tetracycline are relatively
low, at 17.2 and 10.8 %, respectively [4]. The average resist-
ance rate to amoxicillin in Europe is reported to be lower
than 2 %, and the resistance rate to tetracycline is reported
to be below 5 % in most countries [25–27].
We hypothesized that a quadruple regimen containing
amoxicillin and tetracycline would demonstrate a superior
eradication rate and could be a suitable substitute for
triple or sequential regimens in the first-line treatment of
H. pylori infection. The ITT eradication rate of the 14-day
PBAT was 68.7 % and that of 10-day SQT was 74.6 %.
There was no statistically significance difference between


















P = 0.099 
P = 0.240 
Fig. 2 H. pylori eradication rate of 10-day SQT and 14-day PBAT according to the ITT and PP analyses. SQT, sequential therapy; PBAT, quadruple
therapy consists of pantoprazole, bismuth, amoxicillin, and tetracycline; ITT, intention-to-treat; PP, per-protocol
Fig. 3 H. pylori eradication rate of 10-day SQT and 14-day PBAT according to each institution. SQT, sequential therapy; PBAT, quadruple therapy
consists of pantoprazole, bismuth, amoxicillin, and tetracycline; ITT, intention-to-treat
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14-day PBAT was not inferior to 10-day SQT and there-
fore 14-day PBAT could be another treatment option.
However, some controversies in the results and large
heterogeneity in the duration or the first- or second-line
regimen exists in previous studies of amoxicillin- and
tetracycline-containing quadruple regimens. For in-
stance, in a study of the 14-day quadruple regimen, the
eradication rate was 33.3 % in amoxicillin-susceptible H.
pylori-infected patients [28]. In contrast, a Chinese study
showed that the eradication rate of 14-day LBAT (lanso-
prazole, bismuth, amoxicillin, and tetracycline) was
83.8 % (95 % CI: 76.8–90.9 %) [20]. Furthermore, an
RCT performed in Turkey reported the eradication rate
of 14-day EBAT (esomeprazole, bismuth, amoxicillin,
and tetracycline) as 79.0 % (95 % CI: 71–87 %) [21]. Chi
et al. [23] reported that quadruple therapy containing
amoxicillin and tetracycline is an effective regimen to
rescue patients after a failed triple therapy by overcom-
ing the antimicrobial resistance of H. pylori with an
eradication rate of 78 % in ITT and 89 % in PP.
Since H. pylori resistance to amoxicillin and tetracycline
is uncommon, the explanation for the heterogeneous re-
sults could be that both amoxicillin and tetracycline are
weak against H. pylori or possibly there is an antagonistic
effect. However, any possible antagonistic effect between
these two antibiotics is unclear and it is difficult to eluci-
date because data on the gastric bioavailability of tetracyc-
line is lacking [29]. Furthermore, several studies showed a
good eradication rate (78.0–83.8 %), which was not infer-
ior to other regimens, and this positive tendency was also
proven in a recent meta-analysis. Published in 2015, the
meta-analysis, which included 9 RCTs, showed that the
total eradication rate of a quadruple regimen containing
amoxicillin and tetracycline was 78.1 % in ITT and 84.5 %
in PP, which was not inferior to other quadruple regimens
(pooled odds ratio [OR]: 0.9, 95 % CI: 0.42–1.78) [30]. In
subgroup analysis, the eradication rates of 7-day, 10-day,
and 14-day amoxicillin/tetracycline quadruple regimens
were 67.4, 84.6, and 82.3 %, respectively, and the pooled
OR of an amoxicillin/tetracycline quadruple regimen used
as first-line therapy was 2.34 (95 % CI: 0.74–7.42) [30].
In our study, we used different doses and intervals of
PBATcompared with those of previous studies to maximize
subject compliance. In previous studies, bismuth was ad-
ministered at 300 mg and tetracycline at 500 mg, both four
times a day [21, 31]. The mixture of twice a day and four
times a day can influence drug compliance. A recently de-
veloped three-in-one capsule containing bismuth, tetracyc-
line, and metronidazole improved the eradication rate of
bismuth quadruple therapy over 90 % by reducing the
number of medicines and therefore improving patient com-
pliance [32]. In the present clinical trial bismuth 600 mg
twice a day and tetracycline 1000 mg twice a day were
chosen to increase compliance.
Tetracycline is a time-dependent (half-life 8–10 h)
antibiotic agent and has a long post-antibiotic effect
(PAE) [33]. Even though a high blood concentration of
Table 2 Adverse events of the subjects
SQT (n = 195) PBAT (n = 195) p-value
n (%) n (%)
Bloating 21 (22.6) 11 (15.3) 0.097
Epigastric soreness 15 (16.1) 17 (23.6) 0.854
Anorexia 2 (2.2) 1 (1.4) 1.000
Taste distortions 24 (25.8) 4 (5.6) <0.001
Nausea 14 (15.1) 6 (8.3) 0.108
Vomiting 0 2 (2.8) 0.478
Abdominal pain 4 (4.3) 4 (5.6) 0.721
Headache 1 (1.1) 2 (2.8) 1.000
Dyspepsia 4 (4.3) 4 (5.6) 0.721
Diarrhea 2 (2.2) 12 (16.7) 0.014
Constipation 2 (2.2) 3 (4.2) 1.000
Reflux 1 (1.1) 1 (1.4) 0.478
Rash and itching 2 (2.2) 5 (2.8) 0.446
Dizziness 1 (1.1) 0 1.000
Stool color change 0 3 (4.2) 0.246
Total 93 (47.7) 72 (36.9) 0.040
Bold style, means statistical significance
SQT sequential therapy, PBAT quadruple therapy consist of pantoprazole,
bismuth, amoxicillin, and tetracycline
Table 3 Factors associated with eradication failure in amoxicillin- and tetracycline containing quadruple therapy
Factors Crude Univariated Adjusted Multivariated
OR (95 % CI) p-valuea OR (95 % CI)b p-valuec
Age≥ 50 (y) 1.12 (0.54–2.32) 0.763
Female 0.38 (0.31–1.30) <0.0001 0.27 (0.34–1.51) <0.0001
Cigarette smoking 1.35 (0.57–3.20) 0.499
Alcohol drinking 1.42 (0.70–2.88) 0.325
BMI≥ 25 (kg/m2) 2.28 (1.12–4.63) 0.023 2.16 (1.05–4.43) 0.037
OR odds ratio, CI confidence intervals, BMI body mass index
aUnivariate logistic regression
bAdjusted for gender and BMI
cMultivariate logistic regression
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tetracycline does not increase its sterilizing power, it can
inhibit bacterial regrowth for a longer period of time
[34, 35]. From these pharmacokinetic considerations, a
twice-a-day regimen is also appropriate and is likely to
promote patient compliance. The drug compliance in
the present study was 96.1 % in the PBAT group, which
is comparable to that in the SQT group (93.8 %). In
addition, this rate is higher than the 88.6 % [20] and
92.0 % [31] reported by other studies.
This clinical trial had some limitations. First, H. pylori
culture was not routinely performed and we could not
evaluate the eradication rate of amoxicillin- and/or
tetracycline-susceptible H. pylori strains. However, one
center (SNUBH) performed H. pylori cultures and anti-
biotic susceptibility testing by the agar dilution method in
a small number of patients. The first-line or second-line
eradication rate of PBAT was 57.1 % (8/14) in amoxicillin-
and tetracycline-susceptible subjects (data not shown).
More antibiotic susceptibility data are needed in a future
study to confirm the eradication effect of amoxicillin and
tetracycline-containing regimens both in vitro and in vivo.
Second, the limited accuracy of 13C-UBT at 4–6 weeks
after the completion of a bismuth-based treatment that
makes possible, at least in part, a false negative diagnosis
of H. pylori eradication leading to an overestimation of
success rates with the bismuth-based regimen (PBAT).
However, 13C-UBT is a convenient non-invasive method
for H. pylori diagnosis and popularly used for eradication
success. It is very difficult to perform invasive H. pylori
test such as histology or CLOtest via upper endoscopy to
all patients in real clinical setting who did not need
follow-up endoscopy and medical cost is also a problem.
Third, we cannot elucidate the reason why PBAT showed
a lower eradication rate than expected. However, there is a
fairly large eradication rate gap between positive and nega-
tive studies. Further study is needed in the future.
Conclusions
In conclusion, this prospective, multi-center, random-
ized, open-label, parallel design clinical trial demon-
strated that SQT for 10 days appears more effective than
PBAT in spite of frequent adverse events. However, both
10-day SQT and 14-day PBAT did not achieve excellent
eradication rates (>90 %). Thus, additional trials are ne-
cessary to identify a more satisfactory first-line eradica-
tion therapy for H. pylori.
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